Blood & Marrow Transplant Program
The mission of the Blood & Marrow Transplant (BMT) Program in the Taussig Cancer Institute is to provide high quality specialized patient care in a setting of education and research.
How the bone marrow functions
Bone marrow is the soft, spongy center of your bone where blood is produced. Marrow is filled with blood-producing cells, called hematopoietic progenitor cells (HPCs), which develop into mature white blood cells, red blood cells, or platelets.
- White blood cells of various kinds make up part of your immune system for fighting infections.
- Red blood cells are responsible for carrying oxygen throughout your body.
- Platelets clot your blood to prevent bleeding.
HPCs are constantly being produced by your bone marrow, and will develop into the types of cells your body needs. HPCs are sometimes called stem cells.
Types of bone marrow transplants
Most people who need to undergo a blood or marrow transplant have cancer, such as leukemia, lymphoma or multiple myeloma. There are different types of transplants. The type and severity of your disease determine what type of transplant you will need.
An allogeneic transplant involves receiving donor bone marrow, umbilical cord stem cells, or peripheral stem cells. This donor is genetically matched and can be related or unrelated to you.
An autologous transplant involves receiving your own bone marrow or peripheral blood stem cells. A syngeneic transplant involves receiving your identical twin's bone marrow or peripheral stem cells. Here is more information about the specific types of blood or marrow transplants:
An allogeneic transplant involves receiving very high-doses of chemotherapy and/or radiation therapy, followed by the infusion of your donor's bone marrow or peripheral blood stem cells. The high-dose cancer-fighting treatments are given to eliminate the cancer in your body.
The infusion of the new marrow, cord blood, or peripheral stem cells from the donor replaces the bone marrow destroyed by the chemotherapy and/or radiation therapy. Allogeneic transplant patients have the risk of developing a complication called graft-versus-host disease or GvHD. GvHD is a condition where donor cells from the graft attack the patient's (or host's) organs or tissues The condition can be mild and treated on an outpatient basis, or it can be severe and require treatment in the hospital.
A Reduced Intensity allogeneic transplant involves receiving lower doses of chemotherapy and radiation therapy followed by the infusion of your donor's bone marrow or peripheral blood stem cells. The objective is to suppress your own bone marrow by receiving just enough chemotherapy and radiation therapy to allow your donor cells to engraft and grow within you. The hope is these donor cells will mount an immunologic attack against your underlying cancer, generating a response called the “graft-versus-leukemia” effect or “graft-versus-cancer” effect.
You might be a potential candidate for this type of transplant if you have a slow-growing, indolent disorder, such as chronic leukemia, multiple myeloma, myelodysplasia, and low-grade lymphoma.
The mini allogeneic transplant is not appropriate, for example, if you have fast- growing acute leukemia.
An autologous bone marrow transplant involves receiving very high-dose chemotherapy followed by the infusion of your previously collected peripheral stem cells or bone marrow.
The high-dose chemotherapy treatments are given to eliminate the cancer in your body. The infusion of your new marrow or peripheral stem cells replaces the bone marrow destroyed by the chemotherapy and/or radiation therapy.
Before a blood or marrow transplant can be approved as a treatment option, you will have a pre-transplant evaluation. This evaluation includes a complete physical, consultations with members of the Transplant Team, and a comprehensive series of tests. A pre-transplant evaluation provides complete information about your overall health and helps determine if you are eligible for a blood or marrow transplant.
Blood or marrow transplantation as a treatment option
After your transplant doctor has determined you are a good candidate for a transplant, a date for the transplant will be determined and the process of insurance clearance will begin. Please understand that insurance reimbursement for transplantation is not automatic.
If you are to be admitted to the hospital for your transplant, you can expect your stay to be about 3 to 4 weeks, depending on your recovery. During your recovery, you will learn about your new medicines, how to recognize signs of complications and infections, and when you can return to your normal activities.
If an outpatient reduced intensity allogeneic transplant has been approved for you, you will be required to stay within a one-hour drive of Cleveland Clinic’s main campus for at least 100 days after your transplant. At that time, your doctor will evaluate your medical condition to determine where you can continue your follow-up care.
Follow-up care after your transplant includes appointments with your transplant or local doctor and tests to assess how you are recovering.
© Copyright 1995-2016 The Cleveland Clinic Foundation. All rights reserved.
This information is provided by the Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition. This document was last reviewed on: 2/17/2014...#4752